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Abstract
In this thesis, the aim is to work on optimizing the modern machine learning models
for personalized forecasting of Alzheimer Disease (AD) Progression from clinical trial
data. The data comes from the TADPOLE challenge, which is one of the largest
publicly available datasets for AD research (ADNI dataset). The goal of the project
is to develop machine learning models that can be used to perform personalized
forecasts of the participants’ cognitive changes (e.g., ADAS-Cog13 scores) over the
time period of 6,12, 18 and 24 months in the future and the change in Clinical
Status (CS) i.e., whether a person will convert to AD within 2 years or not. This
is important for informing current clinical trials and better design of future clinical
trials for AD. We will work with personalized Gaussian processes as machine learning
models to predict ADAS-Cog13 score and Cox model along with a classifier to predict
the conversion in a patient within 2 years.
This project is done with the collaboration with researchers from the MIT Media
Lab.
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Chapter 1
Introduction
1.1 General Idea
Alzheimer’s disease is a dangerous neural psychological disease which affects around
30 million people worldwide in the year 2015. It causes the state of dementia which
affects the person suffering the disease as well the people around them. The person
affected tend to forget the recent events. It usually affects people who are 65 years
and older. Approximately 6% of people over 65 years suffer from Alzheimer’s[2].
Sadly after spending billions of pounds, thousands of clinical trials, only less than
1% of the clinical trials have successfully gone into the regulatory approval stage
and none of them have found a way to prove the disease-modifying effect[1, 3].
In this project, we are going to use personalized machine learning techniques for
forecasting of AD Progression. For that the basic concept is taken from one of
the papers published jointly by Imperial and MIT researchers[4]. This paper is the
building block on which we will mainly emphasize in this project.
In this paper AD forecasting is done on mainly the three metrics:
• MMSE[5]: Mini-Mental State Examination.
• CDRSB[6]:The Washington University Clinical Dementia Rating Sum of Boxes
score.
• ADAS-Cog13[7]: AD Assessment Scale-Cognitive Subset.
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CS (Clinical Status)[1, 8] is the actual conversion metric used to decide whether
a person is actually converted as an Alzheimer’s patient or not. It can be either
Cognitively Normal(CN); Mild Cognitive Impairment(MCI) or Early Alzheimer Dis-
ease(AD). From a doctor’s point of view these values should always be known for
him or her to decide whether a patient has Alzheimer’s or not. But for many cases
the patient does not have enough recorded data available. That is the main purpose
of the our project. To provide the doctor with an idea about the patient’s conversion
without having an actual ADAS-Cog13 score or not enough CS values.
Figure 1.1: Overview of ADNI Biomarkers[1].Source of Individual pictures:
Wikipedia Commons
The multi-modal feature set consists of demographics, cognitive tests, CSF(Cerebrospinal
Fluid), MRI(Magnetic Resonance Imaging), PET(Positron Emission Tomography),
DTI(Diffusion tensor imaging), Genetics. The ADNI study basically aims to analyze
the bio-markers from the different feature sets in order to predict or forecast AD
progression. The PET data is removed from the dataset due to sparseness. The
cognitive tests consists of mainly the ADAS-Cog13, ADAS-Cog11, CDRSB, MMSE
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etc. among which the ADAS-Cog13 is the forecast feature that we are trying to work
with. Also we have an "Others" feature set which consists of the Clinical Statuses
(i.e., the CN, MCI and AD stages). The different features of ADNI dataset can be
combined to predict the changes in a person from Cognitively Normal (CN) to Mild
Cognitive Impairment (MCI) to stages of early AD which is ultimately the goal of
the project. The forecasted ADAS-Cog13 score and CS actually finally helps predict
whether a person will convert or not.
1.2 Main Focus and Challenges
For our project we are planning to use the CS and the predicted ADAS-Cog13
features of the dataset to predict whether (i) a person will convert to AD or not
and (ii) if the person does convert then how much time it will take for the patient
to convert.
We can assume a two year sliding window of 4 parts with a gap of 6 months between
each visit. So we have four sliding windows. For each window we will calculate the
conversion and assign a label to each conversion. If there is no conversion we will
not assign any label. Finally for each patient we will see after the 4 sliding windows
whether the patient converts to AD or not. If the patient does convert to AD we
will also check at what sliding window the patient does convert to AD. Currently
we have approximately 1737 patients with a maximum of 21 visits per patient, i.e
10 years. Although for many patients the number of visits are way less and also
they do not have a 24th month visit at all. This is also a challenge of the project to
ensure we have 6,12,18,24 months data for all the patients.
It is also imperative to understand that since we are dealing with a lot of patients
here sometimes taking all the patients at a time may not be a feasible idea to express
its features. Sometimes it is better to take around 500 patients at a time to check a
pattern of AD progression and then apply it to all the 1737 patients. Around 1700
patients with around 15 visit approx per person can result in a total of 75k visits
which can be very hard to visualize in a system. We will try to calculate average
values for different changes in CS values or the ADAS-Cog13 score for around 500
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patients (say) and try to generalize if possible. If there is no set pattern we cannot
generalize and we may have to calculate for all the patients and all the visits.
All patients absolutely have their 0th visit registered in the dataset so we will assume
that as the baseline to proceed with. If the patient has CS as (CN=1 or MCI=2)
we will start the calculations for the possible change of that patient into AD. If the
patient has CS as (AD=3) then that patient has already been diagnosed with AD
which is currently not within the scope of the project.Sometimes it has been seen
that the patient can change back to CN from AD and then again back to AD from
CN. Such cases need to be dealt with separately which is currently not being dealt
with although we can try to find a feasible solution later on as we advance in the
project.
1.3 Problem Definition
As stated above in the introduction section the broad idea is whether a person will
convert to AD or not within the next 24 months and if the patient does then how
much time it takes to convert that person to AD. We aim to use the non-parametric
models like Gaussian processes to solve this problem.
In a supervised setting we will use multi-modal features of around 1737 patients as
input. The outcome ADAS-Cog13 scores for each patient simultaneously for 6,12,18
and 24 months is based on the multi-modal features stated above in the introduction
section. This predicted ADAS-Cog13 score is then used along with the CS of each
patient to confirm whether the patient will convert within 2 years or not. In the
dataset we have some patients whose data are missing for a particular visit. For
example, we need the data set of each patient to have 6,12,18,24 months of his or her
visit being recorded as our ultimate aim is to forecast the AD for these 4 different
visits. For those patients that the data is missing currently we will fill them with
their past visit data. Missing data is usually represented in our dataset as -999999.
First we will perform population level GP[9] to train the data. We formulate the
forecasting AD problem as a regression setting and solve it using auto-regressive
GPs[10]. Next the the population level GP[9] is improved by a domain-adaptive
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GPs[11, 12] approach to personalize the population GP for target patients. This
approach we will be using is named personalized GP or pGP[4]. For each of the first
visit of each patient the population model is used instead of the personalized model
as it is the source visit. And all the later visits are which are based on the pGP[4]
are based on personalizing the previous visits. From this GP model we will predict
the ADAS-Cog13 scores for 6,12,18 and 24 months at the same time.
Then, we will use these predicted ADAS-Cog13 scores and change in CS of each
patient to predict whether the patient will actually convert within two years or not.
This is done by first using the Cox model[13] to predict the probabilities of 6,12,18
and 24 months conversion chance. Then using these probabilities and the ground
truth of CS conversion we classify whether a patient will actually convert or not.
11
1.4 Flowchart of the entire project
The below flowchart depicts the entire pipeline of the thesis undertaken:
Figure 1.2: Overview of the entire project pipeline
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Chapter 2
Background
The main background idea of the project was based on Rudovic et al. paper [14]
which extended the approach of Peterson’s paper[4] to predict ADAS-Cog13 score
for each patient for a period of 6,12,18 and 24 months. This paper’s idea[14] was
fundamental in predicting the 4 different time frame ADAS-Cog13 scores of the
future which in turn helped us predict the chance of a patient converting within 2
years using Cox model[13].
Most of the approaches which already exist build on developing models based on
their Clinical Status of each patient like in [15] or [16]. But this paper[4] initially
extends the population level GP into domain adaptive GPs(i.e, the personalized
GPs). Then Rudovic’s paper [14] does this for 6,12,18 and 24 months of ADAS-
Cog13 forecast instead of just 6 months again using the pGP and tGP(target GP)
approach.
2.1 Gaussian Process(GP) Regression Models: The
Idea
Gaussian process is basically a random process which has a collection of random
variables such that every finite linear combination of them is a multivariate normal
distribution.
We have a regression problem to solve using Gaussian processes. The basic idea
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of Gaussian usage in Regression problems was first stated in the paper[17] which
introduces a Gaussian prior in the Bayesian approach[18]. In a Bayesian linear
regression setting[19] let us consider the following model:
y = φT (x)θ + 
 ∼ N (0, σ2)
θ ∼ N (m0, S0)
(2.1)
Here, the Gaussian prior is placed on the parameter θ as p(θ) = N (m0, S0).
We can also represent equation (2.1) as a graphical model as below:
Figure 2.1: Overview of a Basic Bayesian Regression model
Here, xi ∼ RD which represents the input training set and yi ∼ R are the corre-
sponding set of observations.
Now let us calculate the parameter posterior for this model using Bayes’ Theorem[20],
p(θ|X, y) = p(y|X, θ)p(θ)
p(y|X) (2.2)
The p(y|X, θ) is called the likelihood and p(θ) is the parameter prior as mentioned
above.
Also,
p(y|X) =
∫
p(y|X, θ)p(θ) (2.3)
is called the marginal likelihood or evidence. This value is independent of the value
of the parameter θ. Now, using the model in equation (2.1) we can compute the
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posterior in equation (2.2) in a closed form as:
p(θ|X, y) = N (θ|mN , SN) (2.4)
SN = (S
−1
0 + σ
−2ΦTΦ)−1 (2.5)
mN = SN(S
−1
0 m0 + σ
−2ΦTy)−1 (2.6)
Here, the N represents the entire training set.
2.1.1 GP Posterior Predictions
Usually a Gaussian process is defined by the mean function m and the kernel or co-
variance function k. The co-variance or the kernel function should always be positive
semi-definite and symmetric. We can define prediction at any point x∗ using a GP
posterior as,
p(f(x∗)|X, y, x∗) = N (mpost(x∗), kpost(x∗, x∗)) (2.7)
where,
mpost(x∗) = m(x∗) + k(x∗, x)(K + σ2I)−1(y −m(x)) (2.8)
and
kpost(x∗, x∗) = k(x∗, x∗)− k(x∗, x)(K + σ2I)−1k(x, x∗) (2.9)
The (K+σ2I)−1 term is called the Kalman Gain[21], where K is the kernel function
of the GP prior.
Now using the predictive mean and variance we can calculate the posterior belief of
about the function f ,
E[f(x∗)|x∗, X, y] = m(x∗) = k(X, x∗)T (K + σ2I)−1y (2.10)
V[f(x∗)|x∗, X, y] = k(x∗) = k(x∗, x∗)− k(x∗, X)(K + σ2I)−1k(X, x∗) (2.11)
The posterior belief for a function can also be represented graphically as:
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Figure 2.2: Posterior belief of a function
2.2 Analyzing 100 patients with 10+ visits only
I started the work off firstly by focusing on the main research paper which is the
baseline for this idea[1] followed by studying the paper by one Ognjen’s paper[4].
The dataset is taken from the TADPOLE challenge. So going through the dataset
page of the TADPOLE challenge TADPOLE Dataset was very imperative.
Around 100 patients had their CS status classified as CN, MCI or AD in the dataset.
Peterson[4] already created the model for forecasting ADAS-Cog13 for (t+1) visit
only for those 100 patients which had more than 10+ visits only and had at least
17.5% data available.I used that idea and created the source model using auto-
regressive GP[10] for each of the group followed by personalize GP using domain
adaptive GP[11] for new patients for each of the group ultimately creating three
source and three personalized models. I then analyzed the Mean Absolute Error[22]
for each of the different source and personalized models for each new patient when
each of the new patient can either have CN, MCI or AD as group. The models are
created on the basis of multi-modal feature vector as input features. We have the
ADAS-Cog13 score for each of these patients ready which are used as labels.
The following table depicts the the different error rates for the different groups in
terms of Maximum Absolute Errors(MAE):
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Model CN MCI AD Average
SCN 0.0954 14.439 14.137 9.5572
SMCI 5.4696 1.3031 6.8578 4.5435
SAD 4.5478 4.2674 1.9746 3.5966
PCN 0.1029 13.338 10.963 8.1347
PMCI 5.3284 1.3134 5.688 4.1099
PAD 4.2895 3.7544 2.06 3.368
Table 2.1: The MAE rate for different source and personalized GPs for each group
In the above table, the S∗ depicts the source model for each of the three different
Clinical Statuses whereas the P∗ depicts the personalized models for each of the
groups. The last column is the average MAE calculate for each source and person-
alized model.
Next I tried to create a clustering of the three different groups based on the ADAS-
Cog13 score as feature vector. I have used k-means clustering[23] to solve the issue
although we can also use spectral clustering[24] for better visualization. In Spectral
clustering, the eigenvalues are used from the Graph Laplacian Matrix[25] which is
basically the difference between degree matrix and adjacency matrix.
The following figure illustrates the clustering formed based on ADAS-Cog13 score
for the three different groups:
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Figure 2.3: Three different clusters based on ADAS-Cog13 score
• Cluster 1 represents CN cluster.
• Cluster 2 represents MCI cluster.
• Cluster 3 represents AD cluster.
2.3 Survival Analysis
The concept of survival analysis from Daniel’s paper[26] is to be used in this project.
I will be using a right-censored-time-to-event outcome[27] in our case just like in
the paper. These output ADAS-Cog13 scores are handled using survival analysis
techniques and we will be using Cox’s proportional hazards regression model[13]:
log
hj(t)
h0(t)
= β1zj1 + β2zj2 + ...+ βkzjk
where, hj(t) is the hazard function for subject j; which is the normalized proba-
bility(chance) of patient j converting to AD in time t. We have the term t set as
24 months. The term h0(t) is the baseline hazard level to which all subject-specific
hazards hj(t)(i = 1, ..., n) are compared.
For us, the h0t is the ADAS-Cog13 score at t = 0th month visit. The zj1, zj2... are
the predicted feature vector for each subject j. The zj1 is the 1st predicted visit for
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patient j, i.e, the (t+1) timestep of the ADAS-Cog13 score predicted. And similarly
for zj2 is the (t+2) timestep of predicted ADAS-Cog13 score. It goes on for the 4
timesteps for each patient for all the patients. That means we will be predicting the
probability for 6,8,12 and 24 months into the future for each patient.
The β1, β2... values are the unknown weight parameters which can be estimated by
Max likelihood estimation.
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Chapter 3
Data Analysis and Preprocessing
In this part I would provide a detailed explanation on how the dataset was analyzed
and pre-processed before being fed into the GP model. The TADPOLE Dataset
has 1737 patients in total with various missing values , missing visits and other
sparse data with unnecessary noise. This section deals with all those factors by first
analyzing the dataset and then cleaning up the dataset before feeding it to the GP
model followed by the Cox model and classifier.
3.1 Data Analysis
First we perform various forms of data analysis on the dataset to get some idea
about the trends and values in the dataset. The missing values in of ADAS-Cog13
and CS columns were replaced by the previous values in those columns and all the
remaining missing values of the other columns were replaced by -9999999.
Following replacement of the -9999999 missing values with the previous non-missing
values I calculated the the general trajectory of the ADAS-Cog13 scores of the
different patients in various visit times, where each patient represented by their
RIDs(or patient IDs). This is shown in the figure in the folowing page:
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Figure 3.1: Trajectories for few patients based on ADAS-Cog13 scores
Next, I mapped the CN, MCI and AD groups based on ADAS-Cog13 scores
in a single mapping for all the the 1737 patients. And hence, the graph which is
generated is:
Figure 3.2: CN, MCI and AD categories for different ADAS-Cog13 score for each
patient
As we can clearly the CN (represented by the green line) has the lowest range
of ADAS-Cog13 score, followed by MCI (blue line) in the middle and the AD range
(red line) representing the highest ADAS-Cog13 score.
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Although there is a significant amount of variance in the ADAS-Cog13 scores in
each group but it is quite evident that the lower the ADAS-Cog13 score the more
chances that the patient falls into the CN category and higher the score higher the
chances of falling into AD category.
After this I plotted the histograms of ADAS-Cog13 scores per group for each of the
three groups.
Figure 3.3: Histograms of ADAS scores per group
The red colored histograms depict the CN group ADAS-Cog13 scores. The green
colored histograms depict the MCI group ADAS-Cog13 scores. The blue colored
histograms depict the AD group ADAS-cog13 scores.
Mean ADAS-Cog13 of CN group = 8.780
Mean ADAS-Cog13 of MCI group = 15.735
Mean ADAS-Cog13 of AD group = 33.010
Standard Deviation ADAS-Cog13 of CN group = 4.4512
Standard Deviation ADAS-Cog13 of MCI group = 7.5023
Standard Deviation ADAS-Cog13 of AD group = 11.7477
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3.1.1 Table for the number of patients in each group
Figure 3.4: Number of patients per group
There are a total number of 1737 patients. In the above table we see the patients
being divided into the three groups: CN, MCI and AD. Some patients fall under
the category of multiple groups as there is change in group,i.e. a conversion during
the patients’ visit period.
3.1.2 Plot trajectories for each subgroup CN, MCI, AD, i.e,
Plot Average trajectory (Along Time) per group + Stan-
dard Deviation
Figure 3.5: Time vs Average ADAS-Cog13 and Standard Deviation
The blue shaded region is the region of CN Mean ± Standard deviation. The red
shaded region is the region of MCI Mean ± Standard deviation. The green shaded
23
region is the region of AD Mean ± Standard deviation. The solid line is the average
trajectory in each group. The dotted lines are the ± standard deviation lines.
3.1.3 Analysis of the change in ADAS-Cog13 score in the 4
sliding windows
Here we calculate the mean, the maximum , the median, the minimum and the stan-
dard deviation of the difference in ADAS-Cog13 scores for each patient for a span
of 0-2 years. These 0-2 years is split among 4 sliding windows where each window
consists of 6 months.
For each window of 4 steps,
1st Window (0-6 months):
Mean of difference in ADAS-Cog13 score = 0.4487
Max of difference in ADAS-Cog13 score = 25
Min of difference in ADAS-Cog13 score = -46.6700
Median of difference in ADAS-Cog13 score = 0
Standard deviation of difference in ADAS-Cog13 score = 4.7573
2nd Window (6-12 months):
Mean of difference in ADAS-Cog13 score = 0.2893
Max of difference in ADAS-Cog13 score = 48
Min of difference in ADAS-Cog13 score = -42
Median of difference in ADAS-Cog13 score = 0
Standard deviation of difference in ADAS-Cog13 score = 4.8433
3rd Window (12-18 months):
Mean of difference in ADAS-Cog13 score = 0.3295
Max of difference in ADAS-Cog13 score = 14.3300
Min of difference in ADAS-Cog13 score = -16.0000
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Median of difference in ADAS-Cog13 score = 0
Standard deviation of difference in ADAS-Cog13 score = 2.4348
4th Window (18-24 months):
Mean of difference in ADAS-Cog13 score = 1.6002
Max of difference in ADAS-Cog13 score = 33.6700
Min of difference in ADAS-Cog13 score = -14.3400
Median of difference in ADAS-Cog13 score = 1
Standard deviation of difference in ADAS-Cog13 score = 5.1205
The calculation of difference in ADAS-Cog13 score is important as this will be
later used to map against the change in CS values. The feature set will be change
in ADAS-Cog13 scores for each patient against the label of change in CS values.
25
3.2 Data Preprocessing
3.2.1 Histogram of the number of visits visits for each patient
Figure 3.6: Histogram of number of visits per patient
Here we clearly identity which patients have less than 4 visits. Its easier to remove
those patients from this histogram.
There are a total of 241 patients with less than 4 visits.
Patient IDs of those patients: 38, 44, 45, 103, 111, 168, 182, 219, 228, 243, 245, 284,
288, 319, 332, 339, 354, 356, 360, 397, 405, 407, 409, 417, 436, 438, 442, 445, 446,
469, 484, 489, 492, 506, 590, 592, 613, 640, 642, 653, 691, 699, 721,
743, 761, 777, 816, 825, 828, 841, 853, 860, 871, 876, 880, 884, 890,
917, 924, 929, 955, 957, 958, 1013, 1015, 1021, 1033, 1037, 1051, 1083,
1104, 1113, 1137, 1149, 1154, 1184, 1185, 1191, 1192, 1199, 1204, 1210,
1231, 1244, 1248, 1257, 1263, 1277, 1294, 1306, 1322, 1334, 1337, 1338,
1340, 1350, 1354, 1357, 1363, 1366, 1391, 1400, 1409, 1411, 1412, 1420,
1423, 1426, 1435, 2003, 2011, 2057, 2070, 2138, 2171, 2193, 2194, 2199,
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2237, 2278, 2351, 4066, 4085, 4095, 4097, 4139, 4186, 4201, 4209, 4251,
4260, 4264, 4274, 4332, 4348, 4353, 4362, 4403, 4408, 4459, 4474, 4524,
4540, 4546, 4564, 4575, 4583, 4601, 4603, 4609, 4622, 4633, 4688, 4692,
4694, 4708, 4719, 4740, 4745, 4792, 4793, 4798, 4803, 4859, 4907, 4914,
4924, 4943, 4963, 4968, 4976, 4980, 4990, 4994, 4997, 5005, 5016, 5032,
5059, 5075, 5090, 5091, 5102, 5112, 5120, 5138, 5146, 5148, 5150, 5160,
5171, 5184, 5195, 5204, 5205, 5206, 5208, 5209, 5210, 5212, 5213, 5218,
5222, 5224, 5227, 5228, 5231, 5240, 5241, 5242, 5244, 5248, 5250, 5251,
5252, 5253, 5256, 5259, 5261, 5262, 5265, 5266, 5267, 5271, 5272, 5275,
5277, 5278, 5279, 5280, 5282, 5283, 5285, 5287, 5288, 5289, 5290, 5292,
5294, 5295, 5296.
So we can clearly remove these patients while performing calculations because they
have less than 4 visits, i.e, not enough data to predict AD conversion for 6,12,18
and 24 months.
Hence, now we have 1737-241 = 1496 patients with at least 4 visits. Next we select
patients with 5 or 5+ visits with the 0,6,12,18 and 24 months visits available. We
need all these 5 visits at the minimum to calculate whether a patient converts within
2 years or not. If any visit is missing from the first 24 months then it will not be
much value addition to our training dataset. So, we ignore those patients who do
not have 0,6,12,18 and 24 months in their visit history. There were quite a few
patients with 3rd month visit as well; we included those patients as well but did not
include the visit number 3 in calculations as it would make the 4 sliding windows
uneven.
So, from 1496 patients we now select a total of 1141 patients to work with.
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3.2.2 Histogram of the number of visits visits for 1141 pa-
tients
Figure 3.7: Histogram of number of visits for 1141 patients
The figure 3.7 represents the number of visits per patient for the 1141 patients that
has 6,12,18 and 24 months in their visit list.
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3.2.3 Histogram for percentage of missing data in 1141 pa-
tients
Figure 3.8: Histogram of number of visits for 1141 patients
From figure 3.8 we deduce that around 415 patients are such whose more than 90%
data is missing. Thus 415 patients are such that at most 10% is also not available
for them; so we will exclude them.
Hence, finally the number of patients to work with is 1141-415 = 726 patients.
3.2.4 Selecting the features
Initially there were 12739 rows in the tadpole dataset file for 1737 patients. Now,
there are 6584 rows for 726 patients that we have chosen to work with. Also, there
are around 1465 columns available in the feature set but we will try to select around
616 columns as feature set as in Rudovic’s initial paper [4].
• Cognitive Tests: We chose 9 features from the Cognitive Tests namely :-
ADAS-Cog13, ADAS-Cog11, MMSE, CDSRB, RAVLT-immediate subtype,
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RAVLT-percent forgetting subtype, RAVLT-forgetting subtype, FAQ and RAVLT-
learning subtype.
• MRI or Magnetic Resonance Imaging: We chose around 366 MRI biomarkers
which included the three main MRI markers:- ROI cortical thickness, ROI
volume and ROI surface areas.
• DTI or Diffusion Tensor Imaging : We chose 229 DTI features for the patients
based on mainly three types of DTI measurements:- mean diffusivity, radial
diffusivity and axial diffusivity.
• Genetics: We chose 3 features from genetics which are the APOE E4, APGEN1
and APGEN2 columns. The APOE E4 is a huge detector whether a patient
will get Alzheimer’s or not. The APGEN1 and APGEN2 are two types of
APOE E4 based on alleles.
• Demographics: We chose 6 features from Demographics namely :- gender, age,
race, ethnicity, years of education and marital status.
• CSF or Cerebrospinal Fluid: We chose again 3 features from CSF namely
:- amyloid beta, phosphorylated tau and tau. They are important of early
detection of dementia in a patient.
So, finally we have 616 features to work with and 726 patients. The CS, Patient ID
columns are added to the dataset but not used as a column. Also, the ADAS-Cog13
score used as a label in the case of the GP model and not as a feature. The rest 615
columns are used as input features.
We then set the dataset in such a way that first are 615 features followed by the last
4 columns as 6,12,18 and 24 months ADAS-Cog13 values which are to be used as
labels for each visit of a patient, i.e, the (t+1),(t+2),(t+3) and (t+4) ground truth
values; which is shown in the next page.
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Figure 3.9: 6,12,18 and 24 months ADAS-Cog13 ground truth
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Chapter 4
Forecasting of ADAS-Cog13 score
4.1 Z-score normalization
The 726 patients along with the 616 input features are stored in a csv file. Except
the ADAS-Cog13 scores all the remaining 615 features are z-normalized[28]. In z-
normalization each element in the feature matrix is centred to have mean zero and
a scaled standard deviation of 1 which is done column wise.
4.2 Gaussian Process setting
Let us consider a supervised setting which has I(k) = (i(k)ak )
Ak
ak=1
, where I(k) represents
the multi-modal feature vector which we use as input features of Ak patients. The
output score is the predicted ADAS-Cog13 ∈ (0 − 85) which is saved as J (k) =
(j
(k)
ak )
Ak
ak=1
. Now, each patient is represented as a pair of data: (i(k)ak , j
(k)
ak ). This data
pair is represented such that i(k)ak = (i1, ..., it) which has the input features up to tth
visit and we have the corresponding output ADAS-Cog13 scores j(k)ak = (jp). In our
case we have p = 6,12,18 and 24 months i.e, p = t+1,t+2,t+3 and t+4. These data
pairs for each patient are used as training the forecasting model. From here, we
calculate the source GP, the personalized (or domain adaptive GP) and the target
GP[4].
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4.3 Training/Testing of the GP models
We perform a 10-fold cross validation which is independent of patients while training
and testing the GP model. After that the we calculate the Mean Absolute Error
(MAE) of each fold and report the mean(± standard deviation) of all the folds
together. The following are the reported MAE Error for the 10 folds for sGP, pGP
and tGP model:
Figure 4.1: MAE Error for the 10-folds
The mean(± standard deviation) MAE error comes as:
Error sGP pGP tGP
5.35±2.11 5.29±2.05 5.79±2.38
Table 4.1: The mean(±SD) MAE rate for 10-folds
Now, we report the forecasted ADAS-Cog13 for 6,12,18 and 24 months which
are predicted as the output of the GP model as mean and covariance function, i.e,
GP(m,k) where m is the mean function and k is kernel or covariance function. This
is done for each of the three models, i.e, the source model(sGP), the personalized
model(pGP) and the target model(tGP).
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Figure 4.2: sGP model prediction for 6,12,18 and 24 months
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Figure 4.3: pGP model prediction for 6,12,18 and 24 months
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Figure 4.4: tGP model prediction for 6,12,18 and 24 months
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4.4 Comparison
AS we can clear see in terms of MAE Error or by plainly comparing it to the
ground truth the pGP models performs the best among the three models. This is
the advantage of the domain adaptive Auto-regressive GP. This property was clearly
demonstrated in the paper [4]. But through the dataset which we had and performed
sGP,pGP and tGP on that dataset as well; pGP turned yet again to be the best
model amongst the three models.
In the below graph we show the different MAE rate comparison for the three models
for 10-folds:
Figure 4.5: MAE Error comparison for the three models
The blue line is the sGP model, the red is the pGP model and the green is the
tGP model. As we can see, the pGP model has the least error rates in nearly all
folds except the 9th fold where sGP has the lowest error rates and also the 7th fold
where tGP has the lowest error rate. In general, tGP performs the worst and pGP
performs the best.
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Chapter 5
Predicting Conversion in Patients
In this part we use the forecasted ADAS-Cog13 scores for 6,12,18 and 24 months and
the ground truth CS values of the patients to check whether a patient converts within
24 months or not. We will be using Cox model initially to predict the normalized
probability of conversion of patient within the 4 different windows of 6,12,18 and
24 months. And finally an SVM(Support Vector Machines)[29] classifier to predict
whether the patient actually converts or not.
5.1 Setting up the dataset
First, we take the average of all the 6,12,18 and 24 months predictions of ADAS-
Cog13 scores. That is, the average of 6 months scores for sGP, pGP and tGP , the
average of 12 months scores for sGP, pGP and tGP etc. The result is 4 column matrix
with the average ADAS-Cog13 scores of sGP,pGP and tGP for (t+1),(t+2),(t+3)
and (t+4) time period. This 4 columns are placed beside the Patient ID and Clinical
Status columns and overall these 6 columns are stored as a csv file which is shown
in the next page.
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Figure 5.1: 6,12,18 and 24 months average ADAS-Cog13 score along with Clinical
Status
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5.2 Cox model
After this we calculate the difference in ADAS-Cog13 score and the change in Clinical
Status. The change is clinical status column is represented as (0/1). If there is a
conversion then it is set as 1 else it is set as 0. This dataset is then fed into the Cox
model[13]. The ADAS-Cog13 scores of four columns are set as the input variables
and the change in CS column is set as a predictor variable. In MATLAB we coded
the Cox model, where we need an input matrix X and a predictor vector T. Here
we store ADAS-Cog13 as X which is an n-by-p matrix where p is 4 here because 4
columns and n denotes the number of patients. The change in CS column is the T
predictor vector which is n-by-1 vector where n denotes the number of patients.
The Cox model predicts out the p-by-1 vector, i.e, the 4 probabilities of conversion
for each patient. We repeat that for all the n patients to get the 4 probabilities of
conversion for all the patients.
We get all the stats from the Cox model as below:
Figure 5.2: Values returned by the Cox model
We are going to use the p-values from the stats vector as this returns the nor-
malized probability of the patients’ converting chance. In the figure next page we
see the normalized probability of conversion of all the patients in 6,12,18 and 24
months along with the patient ID and the ground truth change in Clinical Status.
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Figure 5.3: 6,12,18 and 24 months normalized probabilities for conversion
The above figure is output of the Cox model showing the normalized probabilities
of conversion for 6,12,18 and 24 months for each patient.
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5.3 Classify whether a patient converts or not
In this part we classify based on the ground truth of change in Clinical Statuses
that whether a patient converts within 24 months or not. We will be using an SVM
classifier to perform the classification. The table shown in figure 5.3 is used for
classification. In the classifier we use the 4 normalized probability columns, i.e, n-
by-4 matrix as the X value or input observations where n is the number of patients.
And we use the n-by-1 change in CS column as the ground truth labels for the
classifier where n is the number of patients.
We calculate the Precision, Recall, F1 Score and Accuracy of the classifier and report
it as below:
Precision Recall F1 Score Accuracy
0.7776 0.7914 0.7845 0.8000
Table 5.1: The different error metrics for the classifier
If we consider true positives, true negatives, false positives and false negatives
from the confusion matrix; then we can define precision, recall, F1 score and accuracy
as:
Precision =
TruePositive
TruePositive+ FalsePositive
Recall =
TruePositive
TruePositive+ FalseNegative
F1Score =
2 ∗ TruePositive
2 ∗ TruePositive+ FalsePositive+ FalseNegative
Accuracy =
TruePositive+ TrueNegative
TruePositive+ FalsePositive+ TrueNegative+ FalseNegative
(5.1)
As we can see we get a moderately highly accuracy of 0.8 which means around 80%
of patients were correctly classified whether they will convert within 2 years or not.
In next page we see the results of the classifier.
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Figure 5.4: Classifier prediction whether each patient will convert or not
The above figure clearly shows the ground truth of conversion in CS for each
patient alongside the predicted conversion in CS from the classifier. This is the final
part of the project which predicts for any random patient that he or she will convert
or not within the span of 2 years.
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Chapter 6
Conclusion
In conclusion, I would like to say that the entire project was completed to help bet-
ter predict the chances of a patient converting to AD. This result can help doctors
a lot in understanding whether a patient actually converts to AD or not within the
span of two years. This in turn can result into huge project in the domain of ML
for healthcare.
There are a few areas where future improvements can be made. We can fill in the
missing data more efficiently for the entire dataset which can thus help us predict
a better value for ADAS-Cog13 scores as a lot of values are missing in the TAD-
POLE dataset. Also, we have used RBF-ISO kernel in our GP models which can
be replaced by ARD kernel as well and a comparison can be drawn as to which
kernel produces better results. The classifier we used was SVM but there are many
other classifiers which can be used for the classification whether a patient converts
or not like Decision Tree classifier[30], Logistic regressor[31] etc. We can also further
extend the approach to say 3 years instead of 2 years and see how the exisiting GP
models perform in them.
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Appendix A
Appendix A
The Ethics Checklist is shown as below:
Figure A.1: Ethics Checklist
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Figure A.2: Ethics Checklist Continued
The above mentioned ethics checklist clearly shows that there is no human,
animal or military involvement or other dual or legal issues and neither any en-
vironmental protection and safety issues are tampered with in this project. Our
project did not directly involve any humans. The dataset which we took from had
data collection from humans which was done by University College London for their
TADPOLE dataset. We just directly took the dataset from the TADPOLE website
with no direct interaction with any human for data collection.
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